Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated... Clin Pharmacokinet (2018) 57:729–737 https://doi.org/10.1007/s40262-017-0591-8 OR IGINAL RESEARCH ARTIC L E Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine 1,2 1,2,5 3,4 • • • Maxim Kuzin Georgios Schoretsanitis Ekkehard Haen 3,4 6,7 1,2 • • • Benedikt Stegmann Christoph Hiemke Gerhard Gru ¨ nder 1,2,8 Michael Paulzen Published online: 2 September 2017 Springer International Publishing AG 2017 Abstract venlafaxine, O-desmethylvenlafaxine and active moiety Background and Objective An increasing trend in pre- (venlafaxine ? O-desmethylvenlafaxine), as well as dose- scribing proton pump inhibitors (PPIs) inevitably increases adjusted plasma concentrations, were compared using non- the risk of unwanted drug–drug interactions (DDIs). The parametrical tests. aim of this study was to uncover pharmacokinetic inter- Results Daily doses of venlafaxine did not differ between actions between two PPIs—omeprazole and pantopra- groups (p = 0.949). The Mann–Whitney U test showed sig- zole—and venlafaxine. nificantly higher plasma concentrations of active moiety, as Methods A therapeutic drug monitoring database con- well as venlafaxine and O-desmethylvenlafaxine, in both PPI tained plasma concentrations of venlafaxine and its active groups [p = 0.023, p = 0.011, p = 0.026, ?29% active metabolite O-desmethylvenlafaxine. We considered three moiety, ?27% venlafaxine, ?36% http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Clinical Pharmacokinetics Springer Journals

Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine

9 pages
Read Article

Loading next page...
 
/lp/springer_journal/effects-of-the-proton-pump-inhibitors-omeprazole-and-pantoprazole-on-HIfKxvRLE4
Publisher
Springer International Publishing
Copyright
Copyright © 2017 by Springer International Publishing AG
Subject
Medicine & Public Health; Pharmacotherapy; Pharmacology/Toxicology; Internal Medicine
ISSN
0312-5963
eISSN
1179-1926
D.O.I.
10.1007/s40262-017-0591-8
Publisher site
See Article on Publisher Site

Abstract

Clin Pharmacokinet (2018) 57:729–737 https://doi.org/10.1007/s40262-017-0591-8 OR IGINAL RESEARCH ARTIC L E Effects of the Proton Pump Inhibitors Omeprazole and Pantoprazole on the Cytochrome P450-Mediated Metabolism of Venlafaxine 1,2 1,2,5 3,4 • • • Maxim Kuzin Georgios Schoretsanitis Ekkehard Haen 3,4 6,7 1,2 • • • Benedikt Stegmann Christoph Hiemke Gerhard Gru ¨ nder 1,2,8 Michael Paulzen Published online: 2 September 2017 Springer International Publishing AG 2017 Abstract venlafaxine, O-desmethylvenlafaxine and active moiety Background and Objective An increasing trend in pre- (venlafaxine ? O-desmethylvenlafaxine), as well as dose- scribing proton pump inhibitors (PPIs) inevitably increases adjusted plasma concentrations, were compared using non- the risk of unwanted drug–drug interactions (DDIs). The parametrical tests. aim of this study was to uncover pharmacokinetic inter- Results Daily doses of venlafaxine did not differ between actions between two PPIs—omeprazole and pantopra- groups (p = 0.949). The Mann–Whitney U test showed sig- zole—and venlafaxine. nificantly higher plasma concentrations of active moiety, as Methods A therapeutic drug monitoring database con- well as venlafaxine and O-desmethylvenlafaxine, in both PPI tained plasma concentrations of venlafaxine and its active groups [p = 0.023, p = 0.011, p = 0.026, ?29% active metabolite O-desmethylvenlafaxine. We considered three moiety, ?27% venlafaxine, ?36%

Journal

Clinical Pharmacokinetics – Springer Journals

Published: Sep 2, 2017

References

  • Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug)—study protocol for a pragmatic randomized controlled trial
    Stingl, JC; Kaumanns, KL; Claus, K; Lehmann, ML; Kastenmuller, K; Bleckwenn, M
  • Drug interactions in the elderly. How multiple drug use increases risk exponentially
    Cadieux, RJ
  • Pharmacokinetic considerations in the treatment of hypertension in risperidone-medicated patients—thinking of clinically relevant CYP2D6 interactions
    Paulzen, M; Haen, E; Gründer, G; Lammertz, SE; Stegmann, B; Schruers, KR
  • Pharmacokinetic patterns of risperidone-associated adverse drug reactions
    Schoretsanitis, G; Stegmann, B; Hiemke, C; Gründer, G; Schruers, KR; Walther, S
  • Risperidone-induced extrapyramidal side effects: is the need for anticholinergics the consequence of high plasma concentrations?
    Schoretsanitis, G; Haen, E; Hiemke, C; Gründer, G; Stegmann, B; Schruers, KR
  • A Canadian Primary Care Sentinel Surveillance Network study evaluating antidepressant prescribing in Canada from 2006 to 2012
    Morkem, R; Barber, D; Williamson, T; Patten, SB
  • Trends in prescription drug use among adults in the United States from 1999–2012
    Kantor, ED; Rehm, CD; Haas, JS; Chan, AT; Giovannucci, EL
  • Arzneiverordnungs-report 2015: Berlin
    Schwabe, U; Paffrath, D
  • Polypharmacy patterns: unravelling systematic associations between prescribed medications
    Calderon-Larranaga, A; Gimeno-Feliu, LA; Gonzalez-Rubio, F; Poblador-Plou, B; Lairla-San Jose, M; Abad-Diez, JM
  • Effect of proton pump inhibitors on the serum concentrations of the selective serotonin reuptake inhibitors citalopram, escitalopram, and sertraline
    Gjestad, C; Westin, AA; Skogvoll, E; Spigset, O
  • Omeprazole preferentially inhibits the metabolism of (+)-(S)-citalopram in healthy volunteers
    Rocha, A; Coelho, EB; Sampaio, SA; Lanchote, VL
  • Increased clozapine plasma concentrations and side effects induced by smoking cessation in 2 CYP1A2 genotyped patients
    Bondolfi, G; Morel, F; Crettol, S; Rachid, F; Baumann, P; Eap, CB
  • O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants
    Fogelman, SM; Schmider, J; Venkatakrishnan, K; Moltke, LL; Harmatz, JS; Shader, RI
  • An assessment of drug-drug interactions: the effect of desvenlafaxine and duloxetine on the pharmacokinetics of the CYP2D6 probe desipramine in healthy subjects
    Patroneva, A; Connolly, SM; Fatato, P; Pedersen, R; Jiang, Q; Paul, J
  • The effects of desvenlafaxine and paroxetine on the pharmacokinetics of the cytochrome P450 2D6 substrate desipramine in healthy adults
    Nichols, AI; Fatato, P; Shenouda, M; Paul, J; Isler, JA; Pedersen, RD
  • The proton pump inhibitor, omeprazole, but not lansoprazole or pantoprazole, is a metabolism-dependent inhibitor of CYP2C19: implications for coadministration with clopidogrel
    Ogilvie, BW; Yerino, P; Kazmi, F; Buckley, DB; Rostami-Hodjegan, A; Paris, BL
  • Therapeutic drug monitoring in pharmacovigilance and pharmacotherapy safety
    Haen, E
  • AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: update 2011
    Hiemke, C; Baumann, P; Bergemann, N; Conca, A; Dietmaier, O; Egberts, K
  • CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine
    Shams, ME; Arneth, B; Hiemke, C; Dragicevic, A; Müller, MJ; Kaiser, R
  • Drug interaction between clopidogrel and proton pump inhibitors
    Liu, TJ; Jackevicius, CA
  • Omeprazole and lansoprazole are mixed inducers of CYP1A and CYP3A in human hepatocytes in primary culture
    Curi-Pedrosa, R; Daujat, M; Pichard, L; Ourlin, JC; Clair, P; Gervot, L
  • Specific and dose-dependent enzyme induction by omeprazole in human beings
    Rost, KL; Brosicke, H; Heinemeyer, G; Roots, I
  • Omeprazole reduces clozapine plasma concentrations. A case report
    Frick, A; Kopitz, J; Bergemann, N
  • Induction of cytochrome P4501A by smoking or omeprazole in comparison with UDP-glucuronosyltransferase in biopsies of human duodenal mucosa
    Buchthal, J; Grund, KE; Buchmann, A; Schrenk, D; Beaune, P; Bock, KW
  • Retrospective evaluation of the effect of omeprazole on clozapine metabolism
    Mookhoek, EJ; Loonen, AJ
  • Influence of CYP2D6 and CYP2C19 genotypes on venlafaxine metabolic ratios and stereoselective metabolism in forensic autopsy cases
    Karlsson, L; Zackrisson, AL; Josefsson, M; Carlsson, B; Green, H; Kugelberg, FC
  • Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active O-desmethyl metabolite
    Klamerus, KJ; Maloney, K; Rudolph, RL; Sisenwine, SF; Jusko, WJ; Chiang, ST
  • Comparison of inhibitory effects of the proton pump-inhibiting drugs omeprazole, esomeprazole, lansoprazole, pantoprazole, and rabeprazole on human cytochrome P450 activities
    Li, XQ; Andersson, TB; Ahlstrom, M; Weidolf, L
  • CYP2C19 polymorphism and proton pump inhibitors
    Klotz, U; Schwab, M; Treiber, G
  • Association between the CYP2C9 polymorphism and the drug metabolism phenotype
    Topic, E; Stefanovic, M; Samardzija, M
  • CYP2C19 polymorphism affects single-dose pharmacokinetics of oral pantoprazole in healthy volunteers
    Gawronska-Szklarz, B; Adamiak-Giera, U; Wyska, E; Kurzawski, M; Gornik, W; Kaldonska, M
  • Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis
    Ichikawa, H; Sugimoto, M; Sugimoto, K; Andoh, A; Furuta, T
  • Omeprazole and CYP2C19 polymorphism: effects of long-term treatment on gastrin, pepsinogen I, and chromogranin A in patients with acid related disorders
    Sagar, M; Bertilsson, L; Stridsberg, M; Kjellin, A; Mardh, S; Seensalu, R
  • Hydroxylation index of omeprazole in relation to CYP2C19 polymorphism and sex in a healthy Iranian population
    Payan, M; Rouini, MR; Tajik, N; Ghahremani, MH; Tahvilian, R
  • Rapid and ultra-rapid metabolizers with CYP2C19*17 polymorphism do not respond to standard therapy with proton pump inhibitors
    Deshpande, N; Sharanya, V; Ravi Kanth, VV; Murthy, HVV; Sasikala, M; Banerjee, R
  • Prediction of antidepressant response to venlafaxine by a combination of early response assessment and therapeutic drug monitoring
    Stamm, TJ; Becker, D; Sondergeld, LM; Wiethoff, K; Hiemke, C; O’Malley, G
  • Serum level of venlafaxine is associated with better memory in psychotic disorders
    Steen, NE; Aas, M; Simonsen, C; Dieset, I; Tesli, M; Nerhus, M
  • Cytochrome P450 2D6 phenotype predicts antidepressant efficacy of venlafaxine: a secondary analysis of 4 studies in major depressive disorder
    Lobello, KW; Preskorn, SH; Guico-Pabia, CJ; Jiang, Q; Paul, J; Nichols, AI
  • Antidepressant exposure as a predictor of clinical outcomes in the treatment of resistant depression in adolescents (TORDIA) study
    Sakolsky, DJ; Perel, JM; Emslie, GJ; Clarke, GN; Wagner, KD; Vitiello, B
  • Interaction of omeprazole, lansoprazole and pantoprazole with P-glycoprotein
    Pauli-Magnus, C; Rekersbrink, S; Klotz, U; Fromm, MF
  • The complexity of active metabolites in therapeutic drug monitoring of psychotropic drugs
    Hendset, M; Haslemo, T; Rudberg, I; Refsum, H; Molden, E
  • Induction of drug efflux protein expression by venlafaxine but not desvenlafaxine
    Bachmeier, CJ; Beaulieu-Abdelahad, D; Ganey, NJ; Mullan, MJ; Levin, GM
  • Effect of proton pump inhibitors on gastric juice volume, gastric pH and gastric intramucosal pH in critically ill patients: a randomized, double-blind, placebo-controlled study
    Gursoy, O; Memis, D; Sut, N
  • Body mass index (BMI) but not body weight is associated with changes in the metabolism of risperidone. A pharmacokinetics-based hypothesis
    Paulzen, M; Haen, E; Stegmann, B; Hiemke, C; Gründer, G; Lammertz, SE
  • A pharmacokinetic study comparing single and repeated oral doses of 20 mg and 40 mg omeprazole and its two optical isomers, S-omeprazole (esomeprazole) and R-omeprazole, in healthy subjects
    Hassan-Alin, M; Andersson, T; Niazi, M; Rohss, K
  • Rabeprazole: a pharmacologic and clinical review for acid-related disorders
    Dadabhai, A; Friedenberg, FK
  • Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics
    Klamerus, KJ; Parker, VD; Rudolph, RL; Derivan, AT; Chiang, ST
  • The effect of age, sex, smoking and co-medication on serum levels of venlafaxine and O-desmethylvenlafaxine under naturalistic conditions
    Unterecker, S; Hiemke, C; Greiner, C; Haen, E; Jabs, B; Deckert, J
  • Therapeutic drug monitoring of racemic venlafaxine and its main metabolites in an everyday clinical setting
    Reis, M; Lundmark, J; Bjork, H; Bengtsson, F

You’re reading a free preview. Subscribe to read the entire article.

Try 2 weeks free now

DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

or browse the journals available

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off

Sign up
for free
Start 14 day
Free Trial